All data are based on the daily closing price as of December 29, 2025
l

Lunit

328130.KQ
28.48 USD
-0.93
-3.16%

Overview

Last close
28.48 usd
Market cap
830.05M usd
52 week high
58.23 usd
52 week low
23.23 usd
Target price
34.16 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
15.5558
Price/Book Value
7.5283
Enterprise Value
913.89M usd
EV/Revenue
17.095
EV/EBITDA
-45.3273

Key financials

Revenue TTM
51.50M usd
Gross Profit TTM
51.50M usd
EBITDA TTM
-46.75M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
277.89M usd
Net debt
43.87M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
  • Symbol
    328130.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Health Information Services
  • CEO
    Mr. Beomseok Brandon Suh
  • Headquarter
    Seoul
  • Web site
    https://www.lunit.io
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top